Submissions from 2017
OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence, Michael B. Chancellor
Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB)., Karel Dewulf, Nitya Abraham, Laura E Lamb, Tomas L Griebling, Naoki Yoshimura, Pradeep Tyagi, Andrew Veerecke, Sarah N Bartolone, Bernadette M M Zwaans, Dirk De Ridder, Ananias Diokno, and Michael B Chancellor
Patient characteristics for different therapeutic strategies in the management ketamine cystitis., Jia-Fong Jhang, Lori A Birder, Michael B Chancellor, and Hann-Chorng Kuo
Development of an interstitial cystitis risk score for bladder permeability., Laura E Lamb, Joseph J Janicki, Sarah N Bartolone, Kenneth M Peters, and Michael B Chancellor
Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide., Tsuyoshi Majima, Pradeep Tyagi, Koji Dogishi, Mahendra Kashyap, Yasuhito Funahashi, Momokazu Gotoh, Michael B Chancellor, and Naoki Yoshimura
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder., Pradeep Tyagi, Mahendra Kashyap, Naoki Yoshimura, Michael Chancellor, and Christopher J Chermansky
Treatment of ulcerative compared to non-ulcerative interstitial cystitis with hyperbaric oxygen: a pilot study., David L Wenzler, Farris Gulli, Maureen Cooney, Michael B Chancellor, Jason Gilleran, and Kenneth M Peters